非小细胞肺癌治疗的最新进展
Recent advances in the management of non-small cell lung cancer.
作者信息
Shojaee Samira, Nana-Sinkam Patrick
机构信息
Division of Pulmonary and Critical Care Medicine, Virginia Commonwealth University, Richmond, USA.
出版信息
F1000Res. 2017 Dec 7;6:2110. doi: 10.12688/f1000research.11471.1. eCollection 2017.
Abstract
Lung cancer is the number one cause of cancer-related death in both men and women. However, over the last few years, we have witnessed improved outcomes that are largely attributable to early detection, increased efforts in tobacco control, improved surgical approaches, and the development of novel targeted therapies. Currently, there are several novel therapies in clinical practice, including those targeting actionable mutations and more recently immunotherapeutic agents. Immunotherapy represents the most significant step forward in eradicating this deadly disease. Given the ever-changing landscape of lung cancer management, here we present an overview of the most recent advances in the management of non-small cell lung cancer.
摘要
肺癌是男性和女性癌症相关死亡的首要原因。然而，在过去几年中，我们见证了治疗效果的改善，这在很大程度上归因于早期检测、加大烟草控制力度、改进手术方法以及新型靶向治疗的发展。目前，临床实践中有几种新型疗法，包括针对可操作突变的疗法以及最近的免疫治疗药物。免疫疗法是根除这种致命疾病方面取得的最重大进展。鉴于肺癌治疗格局不断变化，在此我们概述非小细胞肺癌治疗的最新进展。
相似文献
1
Recent advances in the management of non-small cell lung cancer.
F1000Res. 2017 Dec 7;6:2110. doi: 10.12688/f1000research.11471.1. eCollection 2017.
2
Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
Oncologist. 2019 Nov;24(11):e1070-e1081. doi: 10.1634/theoncologist.2018-0572. Epub 2019 Mar 22.
3
Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review.
JAMA. 2019 Aug 27;322(8):764-774. doi: 10.1001/jama.2019.11058.
4
Developments in targeted therapy & immunotherapy-how non-small cell lung cancer management will change in the next decade: a narrative review.
Ann Transl Med. 2023 Aug 30;11(10):358. doi: 10.21037/atm-22-4444. Epub 2023 Mar 23.
5
Management and future directions in non-small cell lung cancer with known activating mutations.
Am Soc Clin Oncol Educ Book. 2014:e353-65. doi: 10.14694/EdBook_AM.2014.34.e353.
6
Targeted therapy moves to earlier stages of non-small-cell lung cancer: emerging evidence, controversies and future challenges.
Future Oncol. 2021 Oct;17(30):4011-4025. doi: 10.2217/fon-2020-1255. Epub 2021 Aug 2.
7
Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.
Clin Lung Cancer. 2020 May;21(3):e182-e190. doi: 10.1016/j.cllc.2019.11.006. Epub 2019 Nov 21.
8
Developments in systemic therapies for the management of lung cancer.
Intern Med J. 2021 Dec;51(12):2012-2020. doi: 10.1111/imj.15609.
9
Novel Targets, Novel Treatments: The Changing Landscape of Non-Small Cell Lung Cancer.
Cancers (Basel). 2023 May 21;15(10):2855. doi: 10.3390/cancers15102855.
10
Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
Int J Mol Sci. 2021 Jan 8;22(2):593. doi: 10.3390/ijms22020593.
引用本文的文献
1
Lung cancer: Animal model of lung cancer, molecular carcinogenesis of lung cancer, and antitumor effect of against lung cancer.
Open Vet J. 2025 Feb;15(2):482-503. doi: 10.5455/OVJ.2025.v15.i2.1. Epub 2025 Feb 28.
2
Comparative efficacy of various CHIs combined with western medicine for non-small cell lung cancer: A bayesian network meta-analysis of randomized controlled trials.
Front Pharmacol. 2022 Nov 10;13:1037620. doi: 10.3389/fphar.2022.1037620. eCollection 2022.
3
Application Value of Serum Multi-Antibody Combined Detection in Differential Diagnosis and Typing of Lung Cancer.
J Oncol. 2022 Jan 28;2022:8944263. doi: 10.1155/2022/8944263. eCollection 2022.
4
Lamprey Immune Protein Mediates Apoptosis of Lung Cancer Cells Via the Endoplasmic Reticulum Stress Signaling Pathway.
Front Oncol. 2021 Jul 7;11:663600. doi: 10.3389/fonc.2021.663600. eCollection 2021.
5
Endothelial growth factor receptor-mutant lung cancer and post-operative care management: one size does not fit all.
Ann Transl Med. 2020 Dec;8(24):1697. doi: 10.21037/atm-20-4408.
6
Homeopathic Treatment as an Add-On Therapy May Improve Quality of Life and Prolong Survival in Patients with Non-Small Cell Lung Cancer: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Three-Arm, Multicenter Study.
Oncologist. 2020 Dec;25(12):e1930-e1955. doi: 10.1002/onco.13548. Epub 2020 Nov 7.
7
CtBP1 promotes tumour-associated macrophage infiltration and progression in non-small-cell lung cancer.
J Cell Mol Med. 2020 Oct;24(19):11445-11456. doi: 10.1111/jcmm.15751. Epub 2020 Sep 10.
8
Accomplishing an adaptive clinical trial for cancer: Valuation practices and care work across the laboratory and the clinic.
Soc Sci Med. 2020 May;252:112949. doi: 10.1016/j.socscimed.2020.112949. Epub 2020 Mar 24.
9
Drug resistance occurred in a newly characterized preclinical model of lung cancer brain metastasis.
BMC Cancer. 2020 Apr 7;20(1):292. doi: 10.1186/s12885-020-06808-2.
10
Crizotinib-induced immunogenic cell death in non-small cell lung cancer.
Nat Commun. 2019 Apr 2;10(1):1486. doi: 10.1038/s41467-019-09415-3.
本文引用的文献
1
Case series of MET exon 14 skipping mutation-positive non-small-cell lung cancers with response to crizotinib and cabozantinib.
Anticancer Drugs. 2019 Jun;30(5):537-541. doi: 10.1097/CAD.0000000000000765.
2
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.
Ann Oncol. 2017 Jul 1;28(7):1631-1639. doi: 10.1093/annonc/mdx176.
3
Lung cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual.
CA Cancer J Clin. 2017 Mar;67(2):138-155. doi: 10.3322/caac.21390. Epub 2017 Jan 31.
4
Recommendations from the European Society of Thoracic Surgeons (ESTS) regarding computed tomography screening for lung cancer in Europe.
Eur J Cardiothorac Surg. 2017 Mar 1;51(3):411-420. doi: 10.1093/ejcts/ezw418.
5
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.
Lancet Oncol. 2017 Jan;18(1):31-41. doi: 10.1016/S1470-2045(16)30624-6. Epub 2016 Dec 5.
6
Might radiation therapy in addition to chemotherapy improve overall survival of patients with non-oligometastatic Stage IV non-small cell lung cancer?: Secondary analysis of two prospective studies.
BMC Cancer. 2016 Nov 21;16(1):908. doi: 10.1186/s12885-016-2952-3.
7
Pulmonary Resection for Synchronous M1b-cStage IV Non-Small Cell Lung Cancer Patients.
Ann Thorac Surg. 2017 May;103(5):1594-1599. doi: 10.1016/j.athoracsur.2016.08.098. Epub 2016 Nov 15.
8
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study.
Lancet Oncol. 2016 Dec;17(12):1643-1652. doi: 10.1016/S1470-2045(16)30508-3. Epub 2016 Oct 14.
9
Responses to Crizotinib Can Occur in High-Level MET-Amplified Non-Small Cell Lung Cancer Independent of MET Exon 14 Alterations.
J Thorac Oncol. 2017 Jan;12(1):141-144. doi: 10.1016/j.jtho.2016.09.116. Epub 2016 Sep 21.
10
Routine molecular profiling of patients with NSCLC - Authors' reply.
Lancet. 2016 Sep 10;388(10049):1054-1055. doi: 10.1016/S0140-6736(16)31136-9.
Zotero 插件